<DOC>
	<DOCNO>NCT01318694</DOCNO>
	<brief_summary>This study ass safety efficacy alisporivir ( ALV ; DEB025 ) triple therapy [ i.e. , add peginterferon alfa-2a ( PEG ) ribavirin ( RBV ) ] optimize treatment treatment-naïve participant hepatitis C virus ( HCV ) genotype 1 ( GT1 )</brief_summary>
	<brief_title>Efficacy Safety Alisporivir Triple Therapy Chronic Hepatitis C Genotype 1 Treatment-naïve Participants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : Chronic HCV infection HCV genotype 1 No previous treatment hepatitis C infection Serum HCV RNA level ≥ 1000 IU/ml assess quantitative polymerase chain reaction equivalent screening , upper limit Liver evaluation prior baseline : liver biopsy within 3 year Fibroscan within 6 month Exclusion criterion : HCV genotype different genotype 1 coinfection HCV genotype Coinfection Hepatitis B HIV Any cause relevant liver disease HCV Presence history hepatic decompensation Alanine aminotransferase ( ALT ) ≥ 10 time upper limit normal ( ULN ) , 1 episode elevate bilirubin ( &gt; ULN ) past 6 month Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Cyclophilin inhibitor</keyword>
</DOC>